CLRB ▲ +6.7% - Cellectar Biosciences, Inc.
$CLRB CLRBW CLRBZ - Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
15-OCT-2026 07:00 AM ET
Share this post
More filings for $CLRB
CLRB ▼ -0.8% - Cellectar Biosciences, Inc.Nov 4, 2026CLRB ▲ +2.5% - Cellectar Biosciences, Inc.Nov 2, 2026CLRB ▲ +4.9% - Cellectar Biosciences, Inc.Oct 27, 2026CLRB ▲ +0.5% - Cellectar Biosciences, Inc.Sep 29, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $CLRB filing history →💬 Comments
Loading comments…
Leave a comment